Skip to main content
SpringerLink
Log in

Lobular Neoplasia: Atypical Lobular Hyperplasia and Lobular Carcinoma In Situ

  • Chapter
  • First Online:
Breast Disease

  • 2240 Accesses

Abstract

Lobular neoplasia (LN) refers to the spectrum of benign epithelial proliferation including atypical lobular hyperplasia (ALH) and lobular carcinoma in situ (LCIS) (1). It is usually an incidental finding noted at the time of needle or excisional biopsy and lacks distinctive features on imaging or physical exam.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 189.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Haagensen CD, Lane N, Lattes R, et al. Lobular neoplasia (so-called lobular carcinoma in situ) of the breast. Cancer. 1978;42:737–69.

    Article  CAS  PubMed  Google Scholar 

  2. Andersen JA. Lobular carcinoma in situ of the breast. An approach to rational treatment. Cancer. 1977;39:2597–602.

    Article  CAS  PubMed  Google Scholar 

  3. Bauer TL, Pandelidis SM, Rhoads Jr JE. Five-year survival of 100 women with carcinoma of the breast diagnosed by screening mammography and needle-localization biopsy. J Am Coll Surg. 1994;178:427–30.

    CAS  PubMed  Google Scholar 

  4. Page DL, Dupont WD, Rogers LW, Rados MS. Atypical hyperplastic lesions of the female breast. A long-term follow-up study. Cancer. 1985;55(11):2698–708.

    Article  CAS  PubMed  Google Scholar 

  5. Oppong BA, King TA. Recommendations for women with lobular carcinoma in situ (LCIS). Oncology (Williston Park). 2011;25(11):1051–6, 1058.

    Google Scholar 

  6. Urban JA. Bilaterality of cancer of the breast. Biopsy of the opposite breast. Cancer. 1967;20:1867–70.

    Article  CAS  PubMed  Google Scholar 

  7. Rosen PP, Senie R, Schottenfeld D, et al. Noninvasive breast carcinoma: frequency of unsuspected invasion and implications for treatment. Ann Surg. 1979;189(3):377–82.

    Google Scholar 

  8. Simpson PT, Reis-Filho JS, Lakhani S. Lobular carcinoma in situ: biology and pathology, diseases of the breast. Philadelphia: Lippincott Williams and Wilkins; 2004.

    Google Scholar 

  9. Page DL, Schuyler PA, Dupont WD, et al. Atypical lobular hyperplasia as a unilateral predictor of breast cancer risk: a retrospective cohort study. Lancet. 2003;361:125–9.

    Article  PubMed  Google Scholar 

  10. Ottesen GL, Graversen HP, Blichert-Toft M, et al. Lobular carcinoma in situ of the female breast. Short-term results of a prospective nationwide study. The Danish Breast Cancer Cooperative Group. Am J Surg Pathol. 1993;17:14–21.

    Article  CAS  PubMed  Google Scholar 

  11. Marshall LM, Hunter DJ, Connolly JL, et al. Risk of breast cancer associated with atypical hyperplasia of lobular and ductal types. Cancer Epidemiol Biomarkers Prev. 1997;6:297–301.

    CAS  PubMed  Google Scholar 

  12. Hutter RV, Foote Jr FW. Lobular carcinoma in situ. Long term follow-up. Cancer. 1969;24(5):1081–5.

    Article  CAS  PubMed  Google Scholar 

  13. Chuba PJ, Hamre MR, Yap J, et al. Bilateral risk for subsequent breast cancer after lobular carcinoma-in-situ: analysis of surveillance, epidemiology, and end results data. J Clin Oncol. 2005;23:5534–41.

    Article  PubMed  Google Scholar 

  14. Rosen PP, Kosloff C, Lieberman PH, et al. Lobular carcinoma in situ of the breast. Detailed analysis of 99 patients with average follow-up of 24 years. Am J Surg Pathol. 1978;2:225–51.

    Article  CAS  PubMed  Google Scholar 

  15. Li CI, Malone KE, Saltzman BS, et al. Risk of invasive breast carcinoma among women diagnosed with ductal carcinoma in situ and lobular carcinoma in situ, 1988–2001. Cancer. 2006;106:2104–12.

    Article  PubMed  Google Scholar 

  16. Haagensen CD. Diseases of the breast. 2nd ed. Philadelphia: WB Saunders; 1971. p. 503–27.

    Google Scholar 

  17. Wheeler JE, Enterline HT, Roseman JM, et al. Lobular carcinoma in situ of the breast. Long-term follow up. Cancer. 1974;34(3):554–63.

    Article  CAS  PubMed  Google Scholar 

  18. Page DL, Kidd Jr TE, Dupont WD, et al. Lobular neoplasia of the breast: higher risk for subsequent invasive cancer predicted by more extensive disease. Hum Pathol. 1991;22:1232–9.

    Article  CAS  PubMed  Google Scholar 

  19. Hwang H, Barke LD, Mendelson EB, Susnik B. Atypical lobular hyperplasia and classic lobular carcinoma in situ in core biopsy specimens: routine excision is not necessary. Mod Pathol. 2008;21(10):1208–16.

    Article  PubMed  Google Scholar 

  20. Liberman L, Sama M, Susnik B, et al. Lobular carcinoma in situ at percutaneous breast biopsy: surgical biopsy findings. AJR Am J Roentgenol. 1999;173:291–9.

    Article  CAS  PubMed  Google Scholar 

  21. Berg WA, Mrose HE, Ioffe OB. Atypical lobular hyperplasia or lobular carcinoma in situ at core-needle breast biopsy. Radiology. 2001;218:503–9.

    Article  CAS  PubMed  Google Scholar 

  22. Hussain M, Cunnick GH. Management of lobular carcinoma in-situ and atypical lobular hyperplasia of the breast—a review. Eur J Surg Oncol. 2011;37:279–89.

    Article  CAS  PubMed  Google Scholar 

  23. Philpotts LE, Shaheen NA, Jain KS, et al. Uncommon high-risk lesions of the breast diagnosed at stereotactic core-needle biopsy: clinical importance. Radiology. 2000;216:831–7.

    Article  CAS  PubMed  Google Scholar 

  24. Li CI, Anderson BO, Daling JR, Moe RE. Changing incidence of lobular carcinoma in situ of the breast. Breast Cancer Res Treat. 2002;75(3):259–68.

    Article  PubMed  Google Scholar 

  25. Foote FW, Stewart SF. Lobular carcinoma in situ: a rare form of mammary cancer. Am J Pathol. 1941;17(4):491–96.

    Google Scholar 

  26. Page DL, Anderson TJ, Rogers LW. Carcinoma in situ (CIS). Diagnostic histopathology of the breast. New York: Churchill Livingstone; 1987.

    Google Scholar 

  27. Simpson PT, Gale T, Fulford LG, et al. The diagnosis and management of pre-invasive breast disease: pathology of atypical lobular hyperplasia and lobular carcinoma in situ. Breast Cancer Res. 2003;5:258–62.

    Article  PubMed Central  PubMed  Google Scholar 

  28. Shah-Khan MG, Geiger XJ, Reynolds C, et al. Long-term follow-up of lobular neoplasia (atypical lobular hyperplasia/lobular carcinoma in situ) diagnosed on core needle biopsy. Ann Surg Oncol. 2012;19(10):3131–8.

    Article  PubMed  Google Scholar 

  29. Sneige N, Wang J, Baker BA, et al. Clinical, histopathologic, and biologic features of pleomorphic lobular (ductal-lobular) carcinoma in situ of the breast: a report of 24 cases. Mod Pathol. 2002;15:1044–50.

    Article  PubMed  Google Scholar 

  30. Jacobs TW, Pliss N, Kouria G, et al. Carcinomas in situ of the breast with indeterminate features: role of E-cadherin staining in categorization. Am J Surg Pathol. 2001;25:229–36.

    Article  CAS  PubMed  Google Scholar 

  31. Rosai J. Borderline epithelial lesions of the breast. Am J Surg Pathol. 1991;15(3):209–21.

    Article  CAS  PubMed  Google Scholar 

  32. Tavassoli FA. Pathology of the breast. 2nd ed. Norwalk: Appleton and Lange; 1999.

    Google Scholar 

  33. Esserman LJ, Thompson Jr IM, Reid B. Overdiagnosis and overtreatment in cancer: an opportunity for improvement. JAMA. 2013;310(8):797–8.

    Article  CAS  PubMed  Google Scholar 

  34. Referenced with permission from The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer V.1.2013. © National Comprehensive Cancer Network, Inc 2013. All rights reserved. Accessed January 1, 2013. To view the most recent and complete version of the guideline, go online to www.nccn.org. National Comprehensive Cancer Network®, NCCN®, NCCN GUIDELINES®, and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc.

  35. Yeh IT, Dimitrov D, Otto P, et al. Pathologic review of atypical hyperplasia identified by image-guided breast needle core biopsy. Correlation with excision specimen. Arch Pathol Lab Med. 2003;127:49–54.

    PubMed  Google Scholar 

  36. Foster MC, Helvie MA, Gregory NE, et al. Lobular carcinoma in situ or atypical lobular hyperplasia at core-needle biopsy: is excisional biopsy necessary? Radiology. 2004;231:813–9.

    Article  PubMed  Google Scholar 

  37. Elsheikh TM, Silverman JF. Follow-up surgical excision is indicated when breast core needle biopsies show atypical lobular hyperplasia or lobular carcinoma in situ: a correlative study of 33 patients with review of the literature. Am J Surg Pathol. 2005;29(4):534–43.

    Article  PubMed  Google Scholar 

  38. Margenthaler JA, Duke D, Monsees BS, et al. Correlation between core biopsy and excisional biopsy in breast high-risk lesions. Am J Surg. 2006;192:534–7.

    Article  PubMed  Google Scholar 

  39. Brem RF, Lechner MC, Jackman RJ, et al. Lobular neoplasia at percutaneous breast biopsy: variables associated with carcinoma at surgical excision. AJR Am J Roentgenol. 2008;190:637–41.

    Article  PubMed  Google Scholar 

  40. Cangiarella J, Guth A, Axelrod D, et al. Is surgical excision necessary for the management of atypical lobular hyperplasia and lobular carcinoma in situ diagnosed on core needle biopsy? A report of 38 cases and review of the literature. Arch Pathol Lab Med. 2008;132:979–83.

    PubMed  Google Scholar 

  41. Londero V, Zuiani C, Linda A, et al. Lobular neoplasia: core needle breast biopsy underestimation of malignancy in relation to radiologic and pathologic features. Breast. 2008;17:623–30.

    Article  PubMed  Google Scholar 

  42. Rendi MH, Dintzis SM, Lehman CD, et al. Lobular in-situ neoplasia on breast core needle biopsy: imaging indication and pathologic extent can identify which patients require excisional biopsy. Ann Surg Oncol. 2012;19:914–21.

    Article  PubMed  Google Scholar 

  43. Murray MP, Luedtke C, Liberman L, et al. Classic lobular carcinoma in situ and atypical lobular hyperplasia at percutaneous breast core biopsy: outcomes of prospective excision. Cancer. 2013;119(5):1073–9.

    Article  PubMed  Google Scholar 

  44. Nagi CS, O’Donnell JE, Tismenetsky M, et al. Lobular neoplasia on core needle biopsy does not require excision. Cancer. 2008;112:2152–8.

    Article  PubMed  Google Scholar 

  45. Esserman LE, Lamea L, Tanev S, et al. Should the extent of lobular neoplasia on core biopsy influence the decision for excision? Breast J. 2007;13:55–61.

    Article  PubMed  Google Scholar 

  46. Degnim AC, King TA. Surgical management of high-risk breast lesions. Surg Clin North Am. 2013;93(2):329–40.

    Article  PubMed  Google Scholar 

  47. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 2005;97:1652.

    Article  CAS  PubMed  Google Scholar 

  48. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 1998;90:1371–88.

    Article  CAS  PubMed  Google Scholar 

  49. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple outcomes of raloxifene evaluation. JAMA. 1999;281:2189–97.

    Article  CAS  PubMed  Google Scholar 

  50. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006;295:2727–41.

    Article  CAS  PubMed  Google Scholar 

  51. Goss PE, Ingle JN, Ales-Martinez J, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med. 2011;364:2381–91.

    Article  CAS  PubMed  Google Scholar 

  52. Tchou J, Hou N, Rademaker A, et al. Acceptance of tamoxifen chemoprevention by physicians and women at risk. Cancer. 2004;100(9):1800–6.

    Article  PubMed  Google Scholar 

  53. Port ER, Montgomery LL, Heerdt AS, Borgen PI. Patient reluctance toward tamoxifen use for breast cancer primary prevention. Ann Surg Oncol. 2001;8(7):580–5.

    Article  CAS  PubMed  Google Scholar 

  54. Oskar S, Muhsen S, Sung J, et al. Chemoprevention among women with lobular carcinoma in situ. Ann Surg Oncol. 2011;18:S59.

    Google Scholar 

  55. Hartmann LC, Schaid DJ, Woods JE, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med. 1999;340:77–84.

    Article  CAS  PubMed  Google Scholar 

  56. Muhsen S, Junqueira MJ, Park A, et al. Patient characteristics associated with the decision to undergo bilateral prophylactic mastectomy for lobular carcinoma in situ. J Clin Oncol. 2011;29 (S27, A148).

    Google Scholar 

  57. Katipamula R, Degnim AC, Hoskin T, et al. Trends in mastectomy rates at the Mayo Clinic Rochester: effect of surgical year and preoperative magnetic resonance imaging. J Clin Oncol. 2009;27(25):4082–8.

    Article  PubMed Central  PubMed  Google Scholar 

  58. Yao K, Stewart AK, Winchester DJ, Winchester DP. Trends in contralateral prophylactic mastectomy for unilateral cancer: a report from the National Cancer Data Base, 1998–2007. Ann Surg Oncol. 2010;17(10):2554–62.

    Article  PubMed  Google Scholar 

  59. Chung A, Huynh K, Lawrence C, Sim MS, Giuliano A. Comparison of patient characteristics and outcomes of contralateral prophylactic mastectomy and unilateral total mastectomy in breast cancer patients. Ann Surg Oncol. 2012;19(8):2600–6.

    Article  PubMed  Google Scholar 

  60. Arrington AK, Jarosek SL, Virnig BA, Habermann EB, Tuttle TM. Patient and surgeon characteristics associated with increased use of contralateral prophylactic mastectomy in patients with breast cancer. Ann Surg Oncol. 2009;16(10):2697–704.

    Article  PubMed  Google Scholar 

  61. Lostumbo L, Carbine NE, Wallace J. Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database Syst Rev. 2010;11:CD002748.

    PubMed  Google Scholar 

  62. Bodian CA, Perzin KH, Lattes R. Lobular neoplasia. Long term risk of breast cancer and relation to other factors. Cancer. 1996;78(5):1024–34.

    Article  CAS  PubMed  Google Scholar 

  63. Fisher ER, Land SR, Fisher B, et al. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: twelve-year observations concerning lobular carcinoma in situ. Cancer. 2004;100:238–44.

    Article  PubMed  Google Scholar 

  64. Pankratz VS, Hartmann LC, Degnim AC, et al. Assessment of the accuracy of the Gail model in women with atypical hyperplasia. J Clin Oncol. 2008;26(33):5374–9.

    Article  PubMed Central  PubMed  Google Scholar 

  65. Ottesen GL, Graversen HP, Blichert-Toft M, et al. Carcinoma in situ of the female breast. 10 year follow-up results of a prospective nationwide study. Breast Cancer Res Treat. 2000;62(3):197–210.

    Article  CAS  PubMed  Google Scholar 

  66. De Leeuw WJ, Berx G, Vos CB, et al. Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ. J Pathol. 1997;183:404–11.

    Article  PubMed  Google Scholar 

  67. Hwang ES, Nyante SJ, Yi Chen Y, et al. Clonality of lobular carcinoma in situ and synchronous invasive lobular carcinoma. Cancer. 2004;100:2562–72.

    Article  PubMed  Google Scholar 

  68. Lakhani SR, Collins N, Sloane JP, Stratton MR. Loss of heterozygosity in lobular carcinoma in situ of the breast. Clin Mol Pathol. 1995;48:M74–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  69. Bentz JS, Yassa N, Clayton F. Pleomorphic lobular carcinoma of the breast: clinicopathologic features of 12 cases. Mod Pathol. 1998;11(9):814–22.

    CAS  PubMed  Google Scholar 

  70. Downs-Kelly E, Bell D, Perkins GH, et al. Clinical implications of margin involvement by pleomorphic lobular carcinoma in situ. Arch Pathol Lab Med. 2011;135(6):737–43.

    PubMed  Google Scholar 

  71. Ciocca RM, Li T, Freedman GM, Morrow M. Presence of lobular carcinoma in situ does not increase local recurrence in patients treated with breast-conserving therapy. Ann Surg Oncol. 2008;15(8):2263–71.

    Article  PubMed Central  PubMed  Google Scholar 

  72. Apple SK, Matin M, Olsen EP, Moatamed NA. Significance of lobular intraepithelial neoplasia at margins of breast conservation specimens: a report of 38 cases and literature review. Diagn Pathol. 2010;5:54.

    Article  PubMed Central  PubMed  Google Scholar 

  73. Jolly S, Kestin LL, Goldstein NS, Vicini FA. The impact of lobular carcinoma in situ in association with invasive breast cancer on the rate of local recurrence in patients with early-stage breast cancer treated with breast-conserving surgery. Int J Radiat Oncol Biol Phys. 2006;66(2):365–71.

    Article  PubMed  Google Scholar 

  74. Li S, Liu J, Yang Y, et al. Impact of atypical hyperplasia at margins of breast-conserving surgery on the recurrence of breast cancer. J Cancer Res Clin Oncol. 2014;140(4):599–605.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Surgical Oncology, Medical College of Wisconsin, 9200 W Wisconsin Ave, Milwaukee, WI, 53226, USA

    Miraj G. Shah-Khan MD

  2. Department of Surgery, Mayo Clinic, 200 First Street S. W, Rochester, MN, 55905, USA

    James W. Jakub MD

Authors
  1. Miraj G. Shah-Khan MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. James W. Jakub MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Miraj G. Shah-Khan MD .

Editor information

Editors and Affiliations

  1. Advocate Center for Breast Health, Advocate Cancer Institute, Oak Lawn, Illinois, USA

    Adam I. Riker

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer Science+Business Media New York

About this chapter

Cite this chapter

Shah-Khan, M.G., Jakub, J.W. (2015). Lobular Neoplasia: Atypical Lobular Hyperplasia and Lobular Carcinoma In Situ. In: Riker, A. (eds) Breast Disease. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-1145-5_10

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-1145-5_10

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4939-1144-8

  • Online ISBN: 978-1-4939-1145-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation